Cochrane · systematic review · CD011747
Ranolazine for stable angina pectoris
Salazar, CA, Basilio Flores, JE, Veramendi Espinoza, LE, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 1 · 7.1%Low 6 · 42.9%Moderate 4 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Ranolazine (add‐on therapy) versus placebo for stable angina pectoris
Population: patients with stable angina pectoris
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cardiovascular mortality ‐ not reported Ranolazine (add‐on therapy) vs placebo | no estimate extracted | NR | No studies |
Non‐cardiovascular mortality ‐ not reported Ranolazine (add‐on therapy) vs placebo | no estimate extracted | NR | No studies |
All‐cause mortality Ranolazine (add‐on therapy) vs placebo | RR 0.83 [0.26, 2.71] | 3 studies · 2053 participants | Low Downgraded: risk of bias, inconsistency |
Quality of life Scale: 0 to 100. Ranolazine (add‐on therapy) vs placebo | no estimate extracted | 4 studies · 1563 participants | Moderate Downgraded: risk of bias, inconsistency |
AMI incidence Ranolazine (add‐on therapy) vs placebo | RR 0.4 [0.08, 2.07] | 2 studies · 1509 participants | Low Downgraded: risk of bias, inconsistency |
Angina episodes frequency Ranolazine (add‐on therapy) vs placebo | no estimate extracted | 3 studies · 2004 participants | Moderate Downgraded: risk of bias, inconsistency |
Adverse events incidence Ranolazine (add‐on therapy) vs placebo | RR 1.22 [1.06, 1.4] | 3 studies · 2123 participants | Moderate Downgraded: risk of bias, inconsistency |
Ranolazine (monotherapy) versus placebo for stable angina pectoris
Population: patients with stable angina pectoris
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cardiovascular mortality Ranolazine (monotherapy) vs placebo | RR 1.03 [0.56, 1.88] | 1 study · 2604 participants | Low Downgraded: risk of bias |
Non‐cardiovascular mortality ‐ not reported Ranolazine (monotherapy) vs placebo | no estimate extracted | NR | No studies |
All‐cause mortality Ranolazine (monotherapy) vs placebo | RR 1 [0.81, 1.25] | 3 studies · 6249 participants | Low Downgraded: risk of bias |
Quality of life Scale: 0 to 100 Ranolazine (monotherapy) vs placebo | no estimate extracted | 3 studies · 2256 participants | Moderate Downgraded: risk of bias |
AMI incidence Ranolazine (monotherapy) vs placebo | RR 0.88 [0.69, 1.12] | 3 studies · 2983 participants | Low Downgraded: risk of bias |
Angina episodes frequency Ranolazine (monotherapy) vs placebo | no estimate extracted | 2 studies · 402 participants | Low Downgraded: risk of bias |
Adverse events incidence Ranolazine (monotherapy) vs placebo | RR 1.5 [1.12, 2] | 3 studies · 947 participants | Very low Downgraded: risk of bias |